Global Digi-Health Monitor: Calendar Week 2, 2025
AI Accelerates Drug Development: Genesis Therapeutics, Exscientia, Insilico Medicine, and Iambic Therapeutics Are Using Specialized AI Platforms to Revolutionize Drug Discovery
Companies like Genesis Therapeutics, Exscientia, Insilico Medicine, and Iambic Therapeutics are using specialized AI platforms to revolutionize drug discovery through customized chemistry approaches, generative AI, and multimodal transformers. These tools have led to faster development times (some reaching clinical trials in 24 months), improved target selection, and more efficient drug optimization processes.
AI Note-Taking at UChicago Medicine
UChicago Medicine implemented Abridge AI for ambient clinical documentation across 550+ clinicians, allowing doctors to focus more on patient interaction vs. typing notes. The HIPAA-compliant system records and transcribes doctor-patient conversations, requires physician review/approval, shows improved patient satisfaction, and is opt-in for patients.
Healthcare Executives Forecast AI in 2025
Industry leaders predict AI’s healthcare impact will expand through multimodal capabilities (text, images, audio), improved diagnostic imaging, and administrative automation, though clinical adoption faces skepticism due to trust issues and workflow integration challenges. While some see AI revolutionizing areas like drug development and burnout reduction, others expect its primary role to remain in administrative tasks.
NHS App 2.0: How Digital Upgrades Aim to Slash Waiting Lists
The UK government plans to upgrade the NHS App by March 2025 to reduce waiting times for elective care. The improvements will allow patients to manage appointments, choose providers, and access test results digitally. A key goal is to reduce the eight million missed appointments recorded in 2023/2024 by providing more flexibility and control for patients. The app will also support booking diagnostics at nearby Community Diagnostic Centres, including those in non-traditional healthcare settings like shopping malls. By 2025, over 85% of acute trusts are expected to offer appointment access through the app.
Remote Patient Monitoring to Enhance CHF and GLP-1 Care in 2025
Oren Nissim, CEO and cofounder of Brook Health, anticipates that in 2025, remote patient monitoring (RPM) will evolve into an intelligent early warning system for congestive heart failure (CHF). By integrating real-time physiological data with AI-driven pattern recognition, RPM can detect subtle signs of deterioration days before serious symptoms emerge, enabling proactive management and reducing emergency department burdens. Additionally, as the use of GLP-1 medications for diabetes and weight loss increases, RPM will facilitate precise medication management, monitoring adherence, side effects, and impacts across multiple conditions. This integration aims to optimize dosing, manage side effects, and ensure patients achieve maximum benefit from these treatments
